权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Perinuclear Signaling and Cardiac Hypertrophy

核周信号传导和心脏肥大

基本信息

批准号：
10372219
负责人：
Kimberly L Dodge-Kafka
金额：
$ 55.72万
依托单位：
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10372219
关键词：
A kinase anchoring protein Adult Affect American Attenuated B-Lymphocytes Binding Binding Proteins Buffers Calcineurin Calmodulin Cardiac Cardiac Myocytes Catecholamines Cell Nucleus Cells Chronic stress Coupling Cyclic AMP Cyclic AMP-Dependent Protein Kinases Data Dependovirus Disease Gene Expression Genetic Transcription Heart Heart Diseases Heart Hypertrophy Heart failure Hypertrophy In Vitro Individual Infusion procedures Mediating Membrane Modeling Molecular Muscle Muscle Cells Muscle Proteins Norepinephrine Nuclear Nuclear Envelope Pathologic Pathway interactions Patients Pharmacology Phosphotransferases Physiological Prevention Prevention strategy Production Proteins Public Health Publishing Rattus Reagent Receptor Activation Receptor Signaling Recombinants Regulation Sarcoplasmic Reticulum Scaffolding Protein Second Messenger Systems Signal Transduction Small Interfering RNA Specificity Syndrome Testing Therapeutic Ventricular Work beta-adrenergic receptor calcineurin phosphatase cardiovascular disorder prevention cell growth design experimental study fighting gene induction in vivo inhibitor mortality nanobodies novel novel strategies novel therapeutics pressure prevent protein B receptor receptor internalization response scaffold side effect therapeutically effective tool transcription factor

项目摘要

Stimulation of the b-adrenergic receptor (bAR) during the flight-or-fight response increases contractility through protein kinase A (PKA)-stimulated Ca2+ fluxes at the sarcoplasmic reticulum (SR). However, chronic stress on the heart leads to long-term stimulation of the bAR by increased circulating catecholamines, resulting in pathological remodeling due to Ca2+-mediated gene transcription. These divergent responses to bAR activation and Ca2+ signaling suggests that multiples pools of bAR-regulated PKA activity exist in the cardiac myocyte. We suggest that internal bARs at the nuclear envelope activate a PKA-stimulated perinuclear Ca2+ signals that induce pathological gene transcription without affecting cardiac contractility. Therefore, reagents that can block nuclear bAR and attenuate perinuclear Ca2+ transients should prevent disease initiation and/or progression without affecting contractility. Our preliminary data finds that PKA bound to the nuclear envelope located scaffolding protein muscle A-kinase anchoring protein b (mAKAPb) responds to internal bARs to initiate perinuclear Ca2+ transients that stimulate pathological gene transcription. The central hypothesis of this proposal is that targeting mAKAPb signalosomes will modulate nuclear b-AR-mediated PKA and Ca2+ responses that induce pathological disease, without inhibiting, and in fact, maintaining cardiac contractility. Specific Aim 1: Stimulation of a nuclear pool of Ca2+ is required for induction of cardiac hypertrophy. In this Aim, we will buffer the mAKAPb-stimulated perinuclear Ca2+ pool using a specifically localized Ca2+ binging protein in order to determine the importance of this pool for induction of cardiac hypertrophy in adult rat ventricular myoytes. Using adeno-associated virus to deliver the mAKAPb-targeted Ca2+ “buffer” to the cardiac myocytes in vivo, we will determine the effect on pathological remodeling induced by pressure overload and catecholamine infusion. Importantly, the effect of buffering perinuclear Ca2+ on contractility will be investigated. Specific Aim 2: Inhibition of mAKAPb-bound PKA blocks induction of cardiac hypertrophy. This Aim will use tools that selectively modulate only mAKAPb-bound PKA to demonstrate that the associated kinase is both necessary and sufficient for induction of cardiac hypertrophy in vitro and in vivo, while not regulating contractility. Specific Aim 3: A nuclear bAR receptor is responsible for cardiac hypertrophy. Using pharmacological inhibitors, mAKAP-targeted nanobodies that inhibit specifically nuclear b-AR activation, and siRNA against specific b-AR subtypes, we will test the hypothesis that internal, nuclear located bARs are responsible for induction of cardiac hypertrophy. However, modulating these receptors should not affect contractility. Through these Aims, this proposal will define a novel signaling compartment orchestrated by mAKAPb that is required for pathological gene transcription and induction of cardiac disease, but does not affect contractility. Furthermore, completion of this project will reveal how targeting mAKAPb signalosomes can be therapeutically beneficial in the prevention of cardiac remodeling and heart failure.

在逃跑或战斗反应中，b肾上腺素能受体（bAR）的刺激会增加收缩性